Brain tumors pose unique therapeutic challenges due to the special characteristics of the brain. Among them, gliomas-the most common primary malignant brain tumors-remain among the most devastating cancers, with limited treatment options despite recent advances in medicine. Our laboratory integrates clinical and multi-omics data to elucidate the biological mechanisms underlying treatment resistance and to identify novel therapeutic vulnerabilities. Given the pronounced heterogeneity of gliomas, we focus on developing individualized precision medicine strategies and dissecting cellular interactions within the tumor microenvironment. Ultimately, our goal is to translate these insights into improved outcomes and better lives for patients with brain tumors.
Curriculum Vitae
- –2025- Assistant Professor, Graduate School of Health Science and Technology, UNIST
- –2021-2025, Postdoctoral Research Scientist, Department of Systems Biology, Columbia University
- –2011-2019, Clinical Fellow, Department of Neurosurgery, Samsung Medical Center, Sunkyunkwan University College of Medicine
- –2014-2015, Clinical Fellow Department of Pediatric Neurosurgery, Asan Medical Center, University of Ulsan, College of Medicine
- -2010-2014, Resident, Department of Neurosurgery, Asan Medical Center, University of Ulsan, College of Medicine
Academic Credential
- –2016-2019, PhD, Health Science and Technology, Sunkyunkwan University
- –2011-2014, MS, Medicine, University of Ulsan College of Medicine
- –2003-2009, MD, Ewha Womans University College of Medicine
Awards
- –Academic award (Best paper in basic science), The Korean Brain Tumor Society, 2020
- –Academic award (Best paper in basic science), The Korean Neurosurgical Society, 2020
Publications
- –A computational framework for mapping isoform landscapes and regulatory mechanisms from spatial transcriptomics data. bioRxiv. 2025 May. https://www.biorxiv.org/content/10.1101/2025.05.02.651907v1
- –A Multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. Cancer Medicine. 2023, August. https://doi.org/10.1002/cam4.62
- –Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma. Cancer Letters. 2023, July 570:216329. 10.1016/j.canlet.2023.216329
- –Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type glioblastoma. Genome Medicine. 2023, March. 10.1186/s13073-023-01165-8
- -Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death & Disease. 2021, April 07;12(4):374
- -Therapeutic efficacy of GC1118, a novel anti-EGFR antibody, against glioblastoma with high EGFR amplification in patient-derived xenografts. Cancer (Basel). 2020, October 31; 12(11):3210
- -Hypermuagenesis in untreated adult gliomas due to inherited mismatch mutations. Int J Cancer. 2019 Jun 15;144(12):3023-3030
- -Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018 Oct;50(10):1399-141
